Cargando…
P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430872/ http://dx.doi.org/10.1097/01.HS9.0000846452.85760.1b |
| _version_ | 1784779896602492928 |
|---|---|
| author | Fu, W. Li, W. Hu, J. An, G. Wang, Y. Fu, C. Chen, L. Jin, J. Cen, X. Ge, Z. Cai, Z. Niu, T. Qi, M. Gai, X. Li, Q. Liu, W. Liu, W. Yang, X. Chen, X. Lu, J. |
| author_facet | Fu, W. Li, W. Hu, J. An, G. Wang, Y. Fu, C. Chen, L. Jin, J. Cen, X. Ge, Z. Cai, Z. Niu, T. Qi, M. Gai, X. Li, Q. Liu, W. Liu, W. Yang, X. Chen, X. Lu, J. |
| author_sort | Fu, W. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430872 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94308722022-08-31 P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS Fu, W. Li, W. Hu, J. An, G. Wang, Y. Fu, C. Chen, L. Jin, J. Cen, X. Ge, Z. Cai, Z. Niu, T. Qi, M. Gai, X. Li, Q. Liu, W. Liu, W. Yang, X. Chen, X. Lu, J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430872/ http://dx.doi.org/10.1097/01.HS9.0000846452.85760.1b Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Fu, W. Li, W. Hu, J. An, G. Wang, Y. Fu, C. Chen, L. Jin, J. Cen, X. Ge, Z. Cai, Z. Niu, T. Qi, M. Gai, X. Li, Q. Liu, W. Liu, W. Yang, X. Chen, X. Lu, J. P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS |
| title | P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS |
| title_full | P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS |
| title_fullStr | P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS |
| title_full_unstemmed | P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS |
| title_short | P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS |
| title_sort | p895: daratumumab, bortezomib, and dexamethasone (d-vd) versus bortezomib and dexamethasone (vd) alone in chinese patients with relapsed or refractory multiple myeloma (rrmm): updated analysis of lepus |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430872/ http://dx.doi.org/10.1097/01.HS9.0000846452.85760.1b |
| work_keys_str_mv | AT fuw p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT liw p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT huj p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT ang p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT wangy p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT fuc p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT chenl p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT jinj p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT cenx p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT gez p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT caiz p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT niut p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT qim p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT gaix p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT liq p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT liuw p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT liuw p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT yangx p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT chenx p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus AT luj p895daratumumabbortezomibanddexamethasonedvdversusbortezomibanddexamethasonevdaloneinchinesepatientswithrelapsedorrefractorymultiplemyelomarrmmupdatedanalysisoflepus |